Posted by Michael Wonder on 19 Sep 2021
GSK receives CHMP positive opinions recommending approval of Nucala (mepolizumab) in three additional eosinophil driven diseases
17 September 2021 - If approved in Europe, mepolizumab would be the only treatment indicated for use in four eosinophil-driven diseases.
GlaxoSmithKline today announced that the EMA CHMP has issued positive opinions recommending Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5, for use in three eosinophil-driven diseases; hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis and chronic rhinosinusitis with nasal polyps.
